GlassScriptPhysician profile
Frank Almeida
NPI 1518979541
$14,645.03
in general payments reported to CMS, 2019-2025
63 companies · $1,900 in 2025
The $1,900 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,683 · 2020: $1,758 · 2021: $2,450 · 2022: $2,566 · 2023: $2,349 · 2024: $1,939 · 2025: $1,900.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,187.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,084.75 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,418.89 | 2019-2025 | Farxiga, Airsupra, Fasenra |
| Abbvie INC. | $1,305.28 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,137.08 | 2019-2025 | Xifaxan |
| Pfizer INC. | $897.52 | 2019-2025 | |
| Lilly USA, LLC | $859.74 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Amgen INC. | $782.46 | 2020-2025 | Otezla, Repatha, Repatha |
| Glaxosmithkline, LLC. | $780.18 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $632.80 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $517.96 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $266.27 | 2021-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $243.70 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $235.98 | 2019-2023 | Seglentis, Livalo |
| Teva Pharmaceuticals USA, INC. | $224.21 | 2019-2022 | |
| Allergan, INC. | $212.40 | 2019-2020 |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Almeida listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.